LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

Shares of Sun Pharma rose 2 percent to Rs 1,711 in morning trade on July 15, extending their gains for a third straight ...

Indian drugmaker Sun Pharmaceutical Industries together with its subsidiaries announced that further to its intimation dated ...

Sun Pharma shares rose nearly 2 per cent on Tuesday after the company launched Leqselvi, a new treatment for severe alopecia ...

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

Sun Pharmaceutical Industries said that it has launched hair-loss treatment drug LEQSELVI (deuruxolitinib) in the U.S.

Sun Pharmaceutical Industries Limited announced Leqselvi (deuruxolitinib) 8 mg tablets is now available to healthcare providers and people living with severe alopecia areata in the US. Leqselvi is ...

Shares of Sun Pharmaceutical Industries climbed nearly 3 per cent on Tuesday after the firm said it has inked a settlement pact with US-based Incyte Corporation regarding Leqselvi, a drug used for ...

Indian equity indices, Sensex and Nifty, are expected to open on flat-to-higher note on Tuesday following positive global ...

MUMBAI: India’s equity benchmarks snapped a four-session losing streak on Tuesday, as lower-than-expected domestic inflation ...

Going forward, Aadhaar-based OTP verification has been made compulsory for Tatkal ticket bookings on IRCTC. This requirement ...